Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Four forces shaping the insurance playbook in 2026
Insurance is moving past the experimentation phase. The technology has matured and customer demand for personalized, dynamic protection is clear. Yet
Compliance to competitive edge unlock the value of scenarios
Moving beyond box-ticking, scenario analysis empowers organizations to anticipate disruption, allocate resources smartly and build lasting resilience.
The next generation of trustees: preparing for the 2030s
The Pension Schemes Bill has set out a roadmap that will lead to consolidation within the pension schemes market in the run up to the 2030s. The comb

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.